FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989764345> ?p ?o ?g. }

• W2989764345 endingPage "3" @default.
• W2989764345 startingPage "LBA" @default.
• W2989764345 abstract "Introduction: Many older patients (pts) with AML respond to intensive induction chemotherapy (IC), but responses are often short-lived and overall survival (OS) is poor. The benefit of post-remission maintenance treatment (Tx) for pts with AML is unclear, as no therapy has shown to significantly improve OS. CC-486 is an oral hypomethylating agent that allows for prolonged drug exposure during each Tx cycle to sustain therapeutic activity. We hypothesized that prolonged Tx with CC-486 could be effective as post-remission maintenance in AML. Herein, we report the primary results of QUAZAR AML-001 (NCT01757535), a phase III international, randomized, double-blind, placebo (PBO)-controlled study evaluating CC-486 as maintenance therapy in pts aged ≥55 years with AML in first remission following IC. Methods: Eligible pts had de novo or secondary AML, intermediate- or poor-risk cytogenetics, and Eastern Cooperative Oncology Group performance status (ECOG PS) scores of ≤3; had achieved first complete remission (CR) or CR with incomplete count recovery (CRi) after IC, with or without consolidation chemotherapy; and were not candidates for hematopoietic stem-cell transplant (HSCT). Within 4 months of attaining CR/CRi, pts were randomized 1:1 to receive CC-486 300 mg or PBO once-daily on days 1-14 of repeated 28-day Tx cycles. A 21-day dosing schedule was permitted for pts who experienced AML relapse with 5-15% blasts in blood or bone marrow while on-study. Tx could continue indefinitely until the presence of >15% blasts, unacceptable toxicity, or HSCT. The primary endpoint was OS. Secondary endpoints included relapse-free survival (RFS), health-related quality of life (HRQoL), and safety. Samples were collected for exploratory translational endpoints, including measurable residual disease (MRD). Kaplan-Meier estimates of OS and RFS were compared for CC-486 vs. PBO by stratified log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were generated using a stratified Cox proportional hazards model. Results: Between May 2013 and October 2017, 472 pts were randomized to receive CC-486 (n=238) or PBO (n=234). Baseline characteristics were balanced between Tx arms. Median age was 68 years (range 55-86), 91% of pts had de novo AML, and 86% and 14% of pts, respectively, had intermediate-risk or poor-risk cytogenetics. Following induction, 81% of pts achieved a CR and 19% achieved CRi; 80% of pts had received consolidation chemotherapy (45% received 1 consolidation cycle and 31% received 2 consolidation cycles). At a median follow-up of 41.2 months, OS was significantly improved with CC-486 vs. PBO: median OS was 24.7 months vs. 14.8 months from time of randomization, respectively (P=0.0009; HR 0.69 [95%CI 0.55, 0.86]) (FigureA). RFS was also significantly prolonged: median RFS was 10.2 months in the CC-486 arm, compared with 4.8 months in the PBO arm (P=0.0001; HR 0.65 [95%CI 0.52, 0.81]) (Figure B). OS and RFS benefits of CC-486 were demonstrated regardless of baseline cytogenetic risk, the number of prior consolidation cycles received, and CR/CRi status. CC-486 did not adversely impact overall HRQoL vs. PBO, as assessed by mean changes from baseline in HRQoL measures during Tx. CC-486 had a manageable safety profile generally consistent with that of injectable azacitidine. Median exposure to CC-486 was 12 cycles (range 1-80) and to PBO was 6 cycles (1-73). The most frequently reported adverse events (AEs) with CC-486 and PBO were grade 1 or 2 gastrointestinal (GI) events, including nausea (64% and 23%, respectively), vomiting (59% and 10%), and diarrhea (49% and 21%). The most common grade 3-4 AEs were neutropenia (CC-486, 41%; PBO, 24%), thrombocytopenia (23% and 22%), and anemia (14% and 13%). Serious AEs were infrequent, mainly infections, which occurred in 17% of pts in the CC-486 arm and 8% of pts in the PBO arm. Few AEs led to Tx discontinuation, most often GI events (CC-486, 5%; PBO, 0.4%). Conclusions: CC-486 is the first therapy used in the maintenance setting to provide statistically significant and clinically meaningful improvements in both OS and RFS in pts with AML in remission following induction chemotherapy, with or without consolidation. Oral CC-486 has a manageable safety profile and represents a new therapeutic standard for pts with AML in remission. Disclosures Wei: Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: AHW is a former employee of the Walter and Eliza Hall Institute and receives a fraction of its royalty stream related to venetoclax, Research Funding, Speakers Bureau; Macrogenics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Servier: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Honoraria, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees. Döhner:AbbVie, Agios, Amgen, Astellas, Astex, Celator, Janssen, Jazz, Seattle Genetics: Consultancy, Honoraria; AROG, Bristol Myers Squibb, Pfizer: Research Funding; Celgene, Novartis, Sunesis: Honoraria, Research Funding. Montesinos:Abbvie: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Research support; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Teva: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau. Ravandi:BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Orsenix: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Macrogenix: Membership on an entity's Board of Directors or advisory committees, Research Funding. Sayar:Celgene Corporation: Membership on an entity's Board of Directors or advisory committees. Porkka:Celgene: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Selleslag:Celyad: Consultancy; Novartis: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau; Astellas: Consultancy; Daichii Sankyo: Consultancy; Janssen-Cilag: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Astex Otsuka: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau. Sandhu:Takeda: Consultancy; Amgen: Consultancy; Novartis: Consultancy; Bioverativ: Consultancy; Celgene Corporation: Consultancy; Pfizer: Consultancy; Janssen: Consultancy. Giai:BMS: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Beltrami:Ospedale Policlinico San Martino: Employment. Ossenkoppele:Celgene Corporation: Consultancy, Honoraria, Research Funding. La Torre:Celgene Corporation: Employment, Equity Ownership. Skikne:Celgene Corporation: Employment, Equity Ownership. Kumar:Celgene Corporation: Employment, Equity Ownership. Dong:Celgene Corporation: Employment, Equity Ownership. Beach:Celgene Corporation: Employment, Equity Ownership. Roboz:AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Actinium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amphivena: Consultancy, Membership on an entity's Board of Directors or advisory committees; Argenx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astex: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celltrion: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Eisai: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Orsenix: Consultancy, Membership on an entity's Board of Directors or advisory committees; Otsuka: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trovagene: Consultancy, Membership on an entity's Board of Directors or advisory committees." @default.
• W2989764345 created "2019-12-05" @default.
• W2989764345 creator A5000436961 @default.
• W2989764345 creator A5000750846 @default.
• W2989764345 creator A5003121166 @default.
• W2989764345 creator A5003682435 @default.
• W2989764345 creator A5005591514 @default.
• W2989764345 creator A5006048295 @default.
• W2989764345 creator A5012863731 @default.
• W2989764345 creator A5015991333 @default.
• W2989764345 creator A5018592613 @default.
• W2989764345 creator A5018952464 @default.
• W2989764345 creator A5024276965 @default.
• W2989764345 creator A5030235127 @default.
• W2989764345 creator A5031419975 @default.
• W2989764345 creator A5033024327 @default.
• W2989764345 creator A5037134717 @default.
• W2989764345 creator A5039230721 @default.
• W2989764345 creator A5041004365 @default.
• W2989764345 creator A5042528560 @default.
• W2989764345 creator A5043785211 @default.
• W2989764345 creator A5045917230 @default.
• W2989764345 creator A5046911143 @default.
• W2989764345 creator A5047713667 @default.
• W2989764345 creator A5050873337 @default.
• W2989764345 creator A5057804347 @default.
• W2989764345 creator A5063417364 @default.
• W2989764345 creator A5064895172 @default.
• W2989764345 creator A5086626929 @default.
• W2989764345 creator A5087844093 @default.
• W2989764345 creator A5089395073 @default.
• W2989764345 date "2019-11-21" @default.
• W2989764345 modified "2023-10-02" @default.
• W2989764345 title "The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission" @default.
• W2989764345 doi "https://doi.org/10.1182/blood-2019-132405" @default.
• W2989764345 hasPublicationYear "2019" @default.
• W2989764345 type Work @default.
• W2989764345 sameAs 2989764345 @default.
• W2989764345 citedByCount "65" @default.
• W2989764345 countsByYear W29897643452019 @default.
• W2989764345 countsByYear W29897643452020 @default.
• W2989764345 countsByYear W29897643452021 @default.
• W2989764345 countsByYear W29897643452022 @default.
• W2989764345 countsByYear W29897643452023 @default.
• W2989764345 crossrefType "journal-article" @default.
• W2989764345 hasAuthorship W2989764345A5000436961 @default.
• W2989764345 hasAuthorship W2989764345A5000750846 @default.
• W2989764345 hasAuthorship W2989764345A5003121166 @default.
• W2989764345 hasAuthorship W2989764345A5003682435 @default.
• W2989764345 hasAuthorship W2989764345A5005591514 @default.
• W2989764345 hasAuthorship W2989764345A5006048295 @default.
• W2989764345 hasAuthorship W2989764345A5012863731 @default.
• W2989764345 hasAuthorship W2989764345A5015991333 @default.
• W2989764345 hasAuthorship W2989764345A5018592613 @default.
• W2989764345 hasAuthorship W2989764345A5018952464 @default.
• W2989764345 hasAuthorship W2989764345A5024276965 @default.
• W2989764345 hasAuthorship W2989764345A5030235127 @default.
• W2989764345 hasAuthorship W2989764345A5031419975 @default.
• W2989764345 hasAuthorship W2989764345A5033024327 @default.
• W2989764345 hasAuthorship W2989764345A5037134717 @default.
• W2989764345 hasAuthorship W2989764345A5039230721 @default.
• W2989764345 hasAuthorship W2989764345A5041004365 @default.
• W2989764345 hasAuthorship W2989764345A5042528560 @default.
• W2989764345 hasAuthorship W2989764345A5043785211 @default.
• W2989764345 hasAuthorship W2989764345A5045917230 @default.
• W2989764345 hasAuthorship W2989764345A5046911143 @default.
• W2989764345 hasAuthorship W2989764345A5047713667 @default.
• W2989764345 hasAuthorship W2989764345A5050873337 @default.
• W2989764345 hasAuthorship W2989764345A5057804347 @default.
• W2989764345 hasAuthorship W2989764345A5063417364 @default.
• W2989764345 hasAuthorship W2989764345A5064895172 @default.
• W2989764345 hasAuthorship W2989764345A5086626929 @default.
• W2989764345 hasAuthorship W2989764345A5087844093 @default.
• W2989764345 hasAuthorship W2989764345A5089395073 @default.
• W2989764345 hasConcept C104317684 @default.
• W2989764345 hasConcept C126322002 @default.
• W2989764345 hasConcept C142724271 @default.
• W2989764345 hasConcept C143998085 @default.
• W2989764345 hasConcept C150194340 @default.
• W2989764345 hasConcept C168563851 @default.
• W2989764345 hasConcept C190727270 @default.
• W2989764345 hasConcept C204243189 @default.
• W2989764345 hasConcept C204787440 @default.
• W2989764345 hasConcept C27081682 @default.
• W2989764345 hasConcept C2776239401 @default.
• W2989764345 hasConcept C2778461978 @default.
• W2989764345 hasConcept C2778729363 @default.
• W2989764345 hasConcept C55493867 @default.
• W2989764345 hasConcept C71924100 @default.
• W2989764345 hasConcept C86803240 @default.
• W2989764345 hasConceptScore W2989764345C104317684 @default.
• W2989764345 hasConceptScore W2989764345C126322002 @default.
• W2989764345 hasConceptScore W2989764345C142724271 @default.
• W2989764345 hasConceptScore W2989764345C143998085 @default.
• W2989764345 hasConceptScore W2989764345C150194340 @default.
• W2989764345 hasConceptScore W2989764345C168563851 @default.
• W2989764345 hasConceptScore W2989764345C190727270 @default.
• W2989764345 hasConceptScore W2989764345C204243189 @default.

• next